Evidence map›Paper›PMID 36749493›Full record

ReviewCurrent oncology reports2023

Breast MRI: Clinical Indications, Recommendations, and Future Applications in Breast Cancer Diagnosis.

Demi Wekking, Michele Porcu, Pushpamali De Silva, Luca Saba, Mario Scartozzi, Cinzia Solinas

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
17.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 76 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Pretreatment MRI radiomics for predicting pathological Miller-Payne grading in breast cancer following neoadjuvant chemotherapy.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Demi WekkingLocation Academic Medical Centre, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. demi_wekking@outlook.com.ORCID 0000-0002-7612-0944
Michele PorcuRadiology Department, AOU Cagliari, Policlinico Di Monserrato (CA), Monserrato, Italy.
Pushpamali De SilvaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Luca SabaRadiology Department, AOU Cagliari, Policlinico Di Monserrato (CA), Monserrato, Italy.
Mario ScartozziMedical Oncology Department, AOU Cagliari, Policlinico Di Monserrato (CA), Monserrato, Italy.
Cinzia SolinasMedical Oncology Department, AOU Cagliari, Policlinico Di Monserrato (CA), Monserrato, Italy. czsolinas@gmail.com.
Istituto Nazionale di Fisica Nucleare, Sezione di Cagliari · ITBroad Institute · USMassachusetts General Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis article aims to provide an updated overview of the indications for diagnostic breast magnetic resonance imaging (MRI), discusses the available and novel imaging exams proposed for breast cancer detection, and discusses considerations when performing breast MRI in the clinical setting. RECENT

findingsBreast MRI is superior in identifying lesions in women with a very high risk of breast cancer or average risk with dense breasts. Moreover, the application of breast MRI has benefits in numerous other clinical cases as well; e.g., the assessment of the extent of disease, evaluation of response to neoadjuvant therapy (NAT), evaluation of lymph nodes and primary occult tumor, evaluation of lesions suspicious of Paget's disease, and suspicious discharge and breast implants. Breast cancer is the most frequently detected tumor among women around the globe and is often diagnosed as a result of abnormal findings on mammography. Although effective multimodal therapies significantly decline mortality rates, breast cancer remains one of the leading causes of cancer death. A proactive approach to identifying suspicious breast lesions at early stages can enhance the efficacy of anti-cancer treatments, improve patient recovery, and significantly improve long-term survival. However, the currently applied mammography to detect breast cancer has its limitations. High false-positive and false-negative rates are observed in women with dense breasts. Since approximately half of the screening population comprises women with dense breasts, mammography is often incorrectly used. The application of breast MRI should significantly impact the correct cases of breast abnormality detection in women. Radiomics provides valuable data obtained from breast MRI, further improving breast cancer diagnosis. Introducing these constantly evolving algorithms in clinical practice will lead to the right breast detection tool, optimized surveillance program, and individualized breast cancer treatment.

Indexed as

Breast DiseasesBreast NeoplasmsEarly Detection of CancerFemaleHumansMagnetic Resonance ImagingMammographyBreast cancer diagnosisBreast cancer surveillanceBreast MRIDense breastHigh-risk womenMultiparametric

Identifiers

PMID36749493
OpenAlexW4319334178

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.